Cancer Immunotherapy News and Research

RSS

Novel delivery platform enhances effectiveness of cancer immunotherapy and reduces side effects

Immunotherapy is a type of cancer treatment that uses the body's own immune system to help fight cancer. This is by stimulating the immune response to recognize and attack cancer cells more effectively.

16 Sep 2024

Early data shows mRNA-4359 may benefit patients with advanced solid cancers

Interim data from the Phase I dose escalation part of the mRNA cancer immunotherapy (mRNA-4359), show promise in patients with advanced solid cancers.

16 Sep 2024

Early Phase I data shows promise for mRNA cancer immunotherapy in advanced solid cancers

Interim data from the Phase I dose escalation part of the mRNA cancer immunotherapy (mRNA-4359), show promise in patients with advanced solid cancers.

12 Sep 2024

Distinct waves of T cells generated by each dose of combination immunotherapy

A new tool for monitoring immune health patterns over time has revealed how a pair of checkpoint inhibitor therapies works together to recruit new cancer-fighting T cells with every infusion.

29 Aug 2024

16 promising postdoctoral scientists awarded Damon Runyon Fellowships for cancer research

The Damon Runyon Cancer Research Foundation has named 16 new Damon Runyon Fellows, exceptional postdoctoral scientists conducting basic and translational cancer research in the laboratories of leading senior investigators.

28 Aug 2024

UQ study unlocks potential for advanced bladder cancer immunotherapy

University of Queensland research could lead to a more effective immunotherapy treatment against bladder cancer.

27 Aug 2024

Advances in precision medicine enhance cancer immunotherapy

The field of precision medicine, especially in the context of cancer immunotherapy, has seen significant advancements in recent years.

20 Aug 2024

Advancements in neoantigen vaccines offer hope for personalized cancer therapy

The saga of cancer treatment is marked by a relentless pursuit of effectiveness against a disease characterized by complexity and adaptability.

19 Aug 2024

New targets for improved cancer immunotherapy

In the past two decades, immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, showing promising results against various solid tumors. This study reviews recent developments in ICIs, focusing on new targets like T cell immunoreceptors with Ig and ITIM domains (TIGIT), T cell immunoglobulin and mucin domain-containing protein 3 (TIM-3), and lymphocyte activation gene-3 (LAG-3). These targets aim to overcome resistance mechanisms limiting the effectiveness of current therapies, such as anti-PD-1 and anti-CTLA-4. By identifying and developing these new ICIs, researchers hope to improve treatment outcomes and provide new therapeutic options for cancer patients.

14 Aug 2024

EZH2's role in cancer progression and therapy explored

Enhancer of zeste homolog 2 (EZH2) is a catalytic subunit of the Polycomb-repressive complex 2 (PRC2), which plays a crucial role in transcriptional repression through the methylation of histone H3 on lysine 27 (H3K27me3).

9 Aug 2024

Zebrafish model reveals how BCG vaccine triggers immune response in bladder cancer

Using zebrafish "Avatars", an animal model developed by the Cancer Development and Innate Immune Evasion lab at the Champalimaud Foundation (CF), led by Rita Fior, Mayra Martínez-López – a former PhD student at the lab now working at the Universidad de las Américas in Quito, Ecuador – and colleagues studied the initial steps of the Bacillus Calmette-Guérin (BCG) vaccine's action on bladder cancer cells.

8 Aug 2024

Discovery of Tr1 cells as a barrier to cancer immunotherapy offers new hope for treatment

Immunobiologists Robert Schreiber, PhD, (left) and Hussein Sultan, PhD, of Washington University School of Medicine in St. Louis, found that a subset of immune cells that normally puts the brakes on the immune system to prevent it from attacking the body's healthy cells inadvertently also dampens cancer immunotherapy.

7 Aug 2024

METRNL protein identified as key player in cancer progression

A protein called Meteorin-like (METRNL) in the tumor microenvironment saps energy from T cells, thereby severely limiting their ability to fight cancer, according to new research directed by investigators at the Johns Hopkins University School of Medicine and the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy. Finding ways to block the effects of METRNL signaling on tumor-infiltrating T cells may allow these immune cells to regain the energy necessary to eliminate tumors.

7 Aug 2024

Researchers uncover immune system barrier to cancer treatment

By recruiting the immune system to combat tumor cells, immunotherapy has improved survival rates, offering hope to millions of cancer patients. However, only about one in five people responds favorably to these treatments.

7 Aug 2024

Harnessing oncolytic viruses for cancer immunotherapy to improve treatment outcomes

Oncolytic virus (OV)-based immunotherapy has emerged as a promising strategy for cancer treatment, offering a unique potential to selectively target malignant cells while sparing normal tissues.

6 Aug 2024

FDA accepted PD-L1 inhibitor durvalumab for the treatment of endometrial cancer

On June 14, 2024, the U.S. FDA approved AstraZeneca's Durvalumab (IMFINZI®) for primary advanced or recurrent endometrial cancer with mismatch repair deficiency. Endometrial cancer is the most prevalent gynecologic cancer, with an estimated 66,200 new U.S. cases in 2023.

From Sino Biological Inc. 5 Aug 2024

AI reprograms glioblastoma cells into dendritic cells for cancer immunotherapy

In an innovative new study of glioblastoma, scientists used artificial intelligence (AI) to reprogram cancer cells, converting them into dendritic cells (DCs), which can identify cancer cells and direct other immune cells to kill them.

31 Jul 2024

Overcoming cancer relapse with CAR-Enhancer therapy

Even as they have revolutionized the treatment of certain forms of cancer, CAR T-cell therapies have been shadowed by a significant limitation: many patients, including those whose cancer goes into full remission, eventually relapse. In a new study, Dana-Farber Cancer Institute researchers report on a technique with the potential to eliminate that problem.

29 Jul 2024

CD5 knockout using CRISPR boosts CAR T cell therapy efficacy

The effectiveness of CAR T cell therapy against a variety of cancers, including solid tumors, could be boosted greatly by using CRISPR-Cas9 technology to knock out the gene for CD5, a protein found on the surface of T cells, according to a preclinical study from investigators at the University of Pennsylvania's Perelman School of Medicine and Abramson Cancer Center.

19 Jul 2024

Researchers discover key functions of IRF1 in cancer progression and treatment response

Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have uncovered new details about the role of a protein called interferon regulatory factor (IRF1) in cancer progression and treatment response, offering new insight that can potentially help improve the effectiveness of cancer immunotherapy.

15 Jul 2024